Report overview
The global Recombinant Hirudin market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
12000ATU/mg Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Hirudin include Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory and Novus Biologicals, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Hirudin is the most potent natural inhibitor of thrombin. Unlike antithrombin, hirudin binds to and inhibits only the activity of thrombin, with a specific activity on fibrinogen. Therefore, hirudin prevents or dissolves the formation of clots and thrombi (i.e., it has a thrombolytic activity), and has therapeutic value in blood coagulation disorders, in the treatment of skin hematomas and of superficial varicose veins, either as an injectable or a topical application cream. In some aspects, hirudin has advantages over more commonly used anticoagulants and thrombolytics, such as heparin, as it does not interfere with the biological activity of other serum proteins, and can also act on complexed thrombin.
It is difficult to extract large amounts of hirudin from natural sources, so a method for producing and purifying this protein using recombinant biotechnology has been developed. This has led to the development and marketing of a number of hirudin-based anticoagulant pharmaceutical products. Several other direct thrombin inhibitors are derived chemically from hirudin.
Recombinant Hirudin is derived from yeast and the polypeptide chain contains 65 amino acids and its Mw is 6979.5 Dalton which is identical to natural Hirudin except for the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. The Recombinant Hirudin is purified by proprietary chromatographic techniques.
This report aims to provide a comprehensive presentation of the global market for Recombinant Hirudin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hirudin. This report contains market size and forecasts of Recombinant Hirudin in global, including the following market information:
Global Recombinant Hirudin Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Recombinant Hirudin Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Recombinant Hirudin companies in 2023 (%)
We surveyed the Recombinant Hirudin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Hirudin Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Recombinant Hirudin Market Segment Percentages, by Type, 2023 (%)
12000ATU/mg
16000ATU/mg
Global Recombinant Hirudin Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Recombinant Hirudin Market Segment Percentages, by Application, 2023 (%)
Thrombosis Disease
Tumor Disease
Global Recombinant Hirudin Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Recombinant Hirudin Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Hirudin revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Recombinant Hirudin revenues share in global market, 2023 (%)
Key companies Recombinant Hirudin sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Recombinant Hirudin sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott
The Medicines Company
Teva Pharmaceutical
Pfizer
Pentapharm
PrimeGene
Aniara Diagnostica
Bioassay Technology Laboratory
Novus Biologicals
Merck KGaA
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Hirudin, market overview.
Chapter 2: Global Recombinant Hirudin market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Hirudin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Hirudin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Hirudin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
